Form 8-K - Current report:
SEC Accession No. 0001785530-26-000011
Filing Date
2026-05-07
Accepted
2026-05-07 16:11:22
Documents
13
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K howl-20260507.htm   iXBRL 8-K 31044
2 EX-99.1 a03312026ex991.htm EX-99.1 46853
6 GRAPHIC werewolflogohorizontalaa.jpg GRAPHIC 277881
  Complete submission text file 0001785530-26-000011.txt   589790

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20260507.xsd EX-101.SCH 1829
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20260507_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20260507_pre.xml EX-101.PRE 13623
16 EXTRACTED XBRL INSTANCE DOCUMENT howl-20260507_htm.xml XML 2919
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 26953358
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)